Biotek-snakken — Oktober 2019
-
1
-
Tak for linket lahn1 Det ser ud til at Arctic Zymes bliver Biotec P primære forretningsområd fremadrettet. Jeg tror vi gåe en spændende fremtid i møde. Men nu må vi se over de neste kvartaler. Der skal fremgangen gerne bekræftes. Men jeg vil tillade eg at melde kulør som forsigtig optimist....
-
Hej LP90..Vi kommer nok til at vente på nyt eventuelt ved årsrapporten d. 31/10 og efter mødet hos FDA i oktober.
-
Jeg har et frimærke. Jeg arbejder på eventuelt at få Q&A m.m. BH Helge
-
Test
-
Oncology: Kapitalrejsning. https://oncologyventure.com/rights-issue-oct-nov-2019/
-
Bergen Bio stiger 25% lige nu. Administration (FDA) has approved Fast Track Designation for bemcentinib for the treatment of elderly patients with acute myeloid leukaemia (AML) whose disease has relapsed. There are currently no marketed drugs specifically approved for all relapsed AML patients, representing a significant unmet medical need. BerGenBio has ongoing phase 2 trials in this indication and plans to seek regulatory advice from the FDA and European Medicines Agency (EMA) to
-
dertermine the optimal regulatory path for bemcentinib in relapsed AML.
-
Bergenbio-byks etter nyhet om rask prosess i USA
Bergenbio-byks etter nyhet om rask prosess i USA
E24 (e24.no)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind